Therefore, combining antiangiogenesis agents and immune checkpoint blockers would be an attractive strategy for cancer treatment [15], considering that the CD137 activation together with antiangiogenesis enhance the antitumor effects. This evidence concerns the gene TNFRSF9 and cancer.